score_bin	sensitive_predictive_implication	resistance_predictive_implication	prognostic_predictive_implication	feature_type	feature	alteration_type	alteration	tumor_f	total_coverage	exac_af	exac_common	clinvar	sensitive_score_bin	sensitive_therapy_name	sensitive_therapy_strategy	sensitive_therapy_type	sensitive_description	sensitive_citation	sensitive_url	resistance_score_bin	resistance_therapy_name	resistance_therapy_strategy	resistance_therapy_type	resistance_description	resistance_citation	resistance_url	prognostic_score_bin	favorable_prognosis	prognostic_description	prognostic_citation	prognostic_url	number_germline_mutations_in_gene	validation_total_coverage	validation_tumor_f	validation_detection_power	feature_display	preclinical_efficacy_observed	patient_id	tumor_sample_barcode	normal_sample_barcode
Putatively Actionable	Preclinical			Copy Number	CDKN2A	Deletion				0.0	0.0		Putatively Actionable	EPZ015666	PRMT5 inhibition	Targeted therapy	These deletions are typically codeleted with MTAP, which has enhanced dependency on PRMT5 for which there is an inhibitor in clincial development	Kryukov GV, Wilson FH, Ruth JR, et al. MTAP deletion confers enhanced dependency on the PRMT5 arginine methyltransferase in cancer cells. Science. 2016;351(6278):1214-8.	https://doi.org/10.1126/science.aad5214													0				CDKN2A Deletion		MEL-IPI_Pat62	MEL-IPI_Pat62-Tumor-SM-4DK2N	
Investigate Actionability	Clinical evidence			Mutational Burden	High Mutational Burden								Investigate Actionability	Ipilimumab	CTLA-4 inhibition	Immunotherapy	In a study of malignant melanoma using a discovery cohort of 25 patients and a validation cohort of 39 patients, a significantly higher muational burden was seen in patients with a long-term clinical benefit vs. patients with minimal or no benefit to ipilimumab treatment.	Snyder A, Makarov V, Merghoub T, et al. Genetic basis for clinical response to CTLA-4 blockade in melanoma. N Engl J Med. 2014;371(23):2189-99.	https://doi.org/10.1056/NEJMoa1406498													0				 mutations per Mb		MEL-IPI_Pat62		
Investigate Actionability	Preclinical			Somatic Variant	FBXW7	Missense	p.L648I	0.0598	234.0	0.0	0.0		Investigate Actionability	Sirolimus	PI3K/AKT/mTOR inhibition	Targeted therapy	Breast cancer tumor cell lines harboring deletions or mutations in FBXW7 are particularly sensitive to rapamycin treatment, FBXW7 may be a biomarker for human cancers susceptible to treatment with inhibitors of the mTOR pathway.	Mao JH, Kim IJ, Wu D, et al. FBXW7 targets mTOR for degradation and cooperates with PTEN in tumor suppression. Science. 2008;321(5895):1499-502.	https://doi.org/10.1126/science.1162981													0				FBXW7 p.L648I (Missense)		MEL-IPI_Pat62	MEL-IPI_Pat62-Tumor-SM-4DK2N	MEL-IPI_Pat62-Normal-SM-4NFVT
Investigate Actionability			Inferential	Aneuploidy	Whole genome doubling																						Investigate Actionability	0.0	WGD was associated with adverse survival pan-cancer in patients with advanced disease and in cancers with heterogeneous clinical outcomes, even following the development of metastasis.	Bielski CM, Zehir A, Penson AV, et al. Genome doubling shapes the evolution and prognosis of advanced cancers Nat Genet. 2018; 50(8):1189-1195.	https://doi.org/10.1038/s41588-018-0165-1	0						MEL-IPI_Pat62		
Investigate Actionability	FDA-Approved		Inferential	Somatic Variant	PALB2	Missense	p.L698F	0.0216	232.0	0.0	0.0		Investigate Actionability	Olaparib	PARP inhibition	Targeted therapy	The U.S. Food and Drug Administration (FDA) granted approval to olaparib for adult patients with deleterious or suspected deleterous germline or somatic homologous recombination repair (HRR) gene-mutated metastatic castration-resistant prostate cancer (mCRPC), who have progressed following prior treatment with enzalutamide or abiraterone.	AstraZeneca Pharmaceuticals, LP. Lynparza (olaparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208558s014lbl.pdf. Revised May 2020. Accessed 22 October, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208558s014lbl.pdf								Investigate Actionability	1.0	Somatic homologous recombination mutations were predictive of platinum sensitivity compared with cases without homologous recombination mutations in Ovarian, Fallopian Tube, and Peritoneal Carcinomas.	Pennington KP, Walsh T, Harrell MI, et al. Germline and somatic mutations in homologous recombination genes predict platinum response and survival in ovarian, fallopian tube, and peritoneal carcinomas. Clin Cancer Res. 2014;20(3):764-75.	https://doi.org/10.1158/1078-0432.CCR-13-2287	0				PALB2 p.L698F (Missense)	0.0	MEL-IPI_Pat62	MEL-IPI_Pat62-Tumor-SM-4DK2N	MEL-IPI_Pat62-Normal-SM-4NFVT
Investigate Actionability	FDA-Approved		Inferential	Somatic Variant	CHEK2	Splice Site	p.A502T	0.0368	163.0	0.0	0.0		Investigate Actionability	Olaparib	PARP inhibition	Targeted therapy	The U.S. Food and Drug Administration (FDA) granted approval to olaparib for adult patients with deleterious or suspected deleterous germline or somatic homologous recombination repair (HRR) gene-mutated metastatic castration-resistant prostate cancer (mCRPC), who have progressed following prior treatment with enzalutamide or abiraterone.	AstraZeneca Pharmaceuticals, LP. Lynparza (olaparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208558s014lbl.pdf. Revised May 2020. Accessed 22 October, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208558s014lbl.pdf								Investigate Actionability	1.0	Somatic homologous recombination mutations were predictive of platinum sensitivity compared with cases without homologous recombination mutations in Ovarian, Fallopian Tube, and Peritoneal Carcinomas.	Pennington KP, Walsh T, Harrell MI, et al. Germline and somatic mutations in homologous recombination genes predict platinum response and survival in ovarian, fallopian tube, and peritoneal carcinomas. Clin Cancer Res. 2014;20(3):764-75.	https://doi.org/10.1158/1078-0432.CCR-13-2287	0				CHEK2 p.A502T (Splice Site)	0.0	MEL-IPI_Pat62	MEL-IPI_Pat62-Tumor-SM-4DK2N	MEL-IPI_Pat62-Normal-SM-4NFVT
Investigate Actionability	FDA-Approved			Somatic Variant	TSC1	Missense	p.P684L	0.4355	124.0	0.0	0.0		Investigate Actionability	Everolimus	PI3K/AKT/mTOR inhibition	Targeted therapy	Everolimus is indicated for the treatment of subependymal giant cell astrocytoma (SEGA) associated with tuberous sclerosis complex in adults and pediatric patients who are not candidates for curative surgical resection	Novartis Pharmaceuticals Corporation. Afinitor (everolimus) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/022334s044,203985s016lbl.pdf. Revised February 2020. Accessed November 12, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/022334s044,203985s016lbl.pdf													0				TSC1 p.P684L (Missense)		MEL-IPI_Pat62	MEL-IPI_Pat62-Tumor-SM-4DK2N	MEL-IPI_Pat62-Normal-SM-4NFVT
Investigate Actionability	Clinical evidence			Somatic Variant	MSH6	Frameshift	p.-524fs	0.6023	88.0	0.0	0.0		Investigate Actionability	Pembrolizumab	PD-1/PD-L1 inhibition	Immunotherapy	Patients with defects in DNA mismatch repair genes may have enhanced sensitivity to immune checkpoint blockade.	Le DT, Uram JN, Wang H, et al. PD-1 Blockade in Tumors with Mismatch-Repair Deficiency. N Engl J Med. 2015;372(26):2509-20.	https://doi.org/10.1056/NEJMoa1500596													0				MSH6 p.-524fs (Frameshift)		MEL-IPI_Pat62	MEL-IPI_Pat62-Tumor-SM-4DK2N	MEL-IPI_Pat62-Normal-SM-4NFVT
Investigate Actionability	Clinical evidence			Somatic Variant	ERBB3	Splice Site		0.0435	115.0	0.0	0.0		Investigate Actionability	Neratinib	ER signaling inhibition	Targeted therapy	Missesnse mutations may predict sensitivity to HER2 inhibitors	Hyman DM, Piha-Paul SA, Won H, et al. HER kinase inhibition in patients with HER2- and HER3-mutant cancers Nature. 2018; 554(7691):189-194.	https://doi.org/10.1038/nature25475													0				ERBB3  (Splice Site)		MEL-IPI_Pat62	MEL-IPI_Pat62-Tumor-SM-4DK2N	MEL-IPI_Pat62-Normal-SM-4NFVT
Investigate Actionability	Clinical evidence			Somatic Variant	MSH6	Frameshift	p.-524fs	0.5048	105.0	0.0	0.0		Investigate Actionability	Pembrolizumab	PD-1/PD-L1 inhibition	Immunotherapy	Patients with defects in DNA mismatch repair genes may have enhanced sensitivity to immune checkpoint blockade.	Le DT, Uram JN, Wang H, et al. PD-1 Blockade in Tumors with Mismatch-Repair Deficiency. N Engl J Med. 2015;372(26):2509-20.	https://doi.org/10.1056/NEJMoa1500596													0				MSH6 p.-524fs (Frameshift)		MEL-IPI_Pat62	MEL-IPI_Pat62-Tumor-SM-4DK2N	MEL-IPI_Pat62-Normal-SM-4NFVT
Investigate Actionability	Preclinical		Clinical evidence	Somatic Variant	ARID1A	Missense	p.P690S	0.0469	128.0	0.0	0.0		Investigate Actionability	Durvalumab	PD-1/PD-L1 inhibition	Immunotherapy	Loss of function ARID1A mutations may predict sensitivity to immune checkpoint blockade, particularly PD-L1 inhibition. Anti-PD-L1 antibody reduced tumor mutational burden and prolonged survival of mice ARID1A-deficient but not ARID1A-wild-type ovarian tumors.	Shen J, Ju Z, Zhao W, et al. ARID1A deficiency promotes mutability and potentiates therapeutic antitumor immunity unleashed by immune checkpoint blockade. Nat Med. 2018;24(5):556-562.	https://doi.org/10.1038/s41591-018-0012-z								Investigate Actionability	0.0	ARID1A mutations were associated with poorer prognosis in a study of 109 microdissected pancreatic adenocarcinoma tumors.	Witkiewicz AK, Mcmillan EA, Balaji U, et al. Whole-exome sequencing of pancreatic cancer defines genetic diversity and therapeutic targets. Nat Commun. 2015;6:6744.	https://doi.org/10.1038/ncomms7744	0				ARID1A p.P690S (Missense)		MEL-IPI_Pat62	MEL-IPI_Pat62-Tumor-SM-4DK2N	MEL-IPI_Pat62-Normal-SM-4NFVT
Biologically Relevant				Somatic Variant	NTRK1	Missense	p.G344E	0.1711	76.0	0.0	0.0																					0				NTRK1 p.G344E (Missense)		MEL-IPI_Pat62	MEL-IPI_Pat62-Tumor-SM-4DK2N	MEL-IPI_Pat62-Normal-SM-4NFVT
Biologically Relevant				Somatic Variant	ROS1	Missense	p.D1202N	0.4182	275.0	0.0	0.0																					0				ROS1 p.D1202N (Missense)		MEL-IPI_Pat62	MEL-IPI_Pat62-Tumor-SM-4DK2N	MEL-IPI_Pat62-Normal-SM-4NFVT
Biologically Relevant				Somatic Variant	ROS1	Missense	p.A651V	0.0216	370.0	0.0	0.0																					0				ROS1 p.A651V (Missense)		MEL-IPI_Pat62	MEL-IPI_Pat62-Tumor-SM-4DK2N	MEL-IPI_Pat62-Normal-SM-4NFVT
Biologically Relevant				Somatic Variant	AURKB	Missense	p.E174K	0.1549	71.0	2.5e-05	0.0																					0				AURKB p.E174K (Missense)		MEL-IPI_Pat62	MEL-IPI_Pat62-Tumor-SM-4DK2N	MEL-IPI_Pat62-Normal-SM-4NFVT
Biologically Relevant				Somatic Variant	NF1	Nonsense	p.Q1070*	0.7059	34.0	0.0	0.0																					0				NF1 p.Q1070* (Nonsense)		MEL-IPI_Pat62	MEL-IPI_Pat62-Tumor-SM-4DK2N	MEL-IPI_Pat62-Normal-SM-4NFVT
Biologically Relevant				Somatic Variant	NF1	Missense	p.L1975F	0.3691	233.0	0.0	0.0																					0				NF1 p.L1975F (Missense)		MEL-IPI_Pat62	MEL-IPI_Pat62-Tumor-SM-4DK2N	MEL-IPI_Pat62-Normal-SM-4NFVT
Biologically Relevant				Microsatellite Stability	Supporting variants		MSH6 p.-524fs (Frameshift)																									0				Supporting variants: MSH6 p.-524fs (Frameshift)		MEL-IPI_Pat62		
Biologically Relevant				Mutational Signature	COSMIC Signature 7	version 2	0.527																									0				COSMIC Signature (version 2) 7 (53%)		MEL-IPI_Pat62		
Biologically Relevant				Mutational Signature	COSMIC Signature 11	version 2	0.32																									0				COSMIC Signature (version 2) 11 (32%)		MEL-IPI_Pat62		
